Xiaoqian Cheng

Dr. Xiaoqian Cheng

Jerome Canady Research Institute for Advanced Biological and Technological Sciences
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DYDayun Yan
Dayun Yan
ATAnnie Talbot
Annie Talbot
NNNiki Nourmohammadi
Niki Nourmohammadi
XCXiaoqian Cheng
Xiaoqian Cheng
JCJerome Canady
Jerome Canady
Michael KeidarMichael Keidar
Michael Keidar
To date, the significant anti-cancer capacity of cold atmospheric plasma (CAP) on dozens of cancer cell lines has been demonstrated in vitro and in mice models. Conventionally, CAP was directly applied to irradiate cancer cells or tumor tissue. Over past three years, the CAP irradiated media was also found to kill cancer cells as effectively as the direct CAP treatment. As a novel strategy, using the CAP stimulated (CAPs) media has become a promising anti-cancer tool. In this study, we demonstrated several principles to optimize the anti-cancer capacity of the CAPs media on glioblastoma cells and breast cancer cells. Specifically, using larger wells on a multi-well plate, smaller gaps between the plasma source and the media and smaller media volume enabled us to obtain a stronger anti-cancer CAPs media composition without increasing the treatment time. Furthermore, cysteine was the main target of effective reactive species in the CAPs media. Glioblastoma cells were more resistant to the CAPs media than breast cancer cells. Glioblastoma cells consumed the effective reactive species faster than breast cancer cells did. In contrast to nitric oxide, hydrogen peroxide was more likely to be the effective reactive species.

1 December 2016 in Acta Biomaterialia
Verified
Journal Article
Closed access
MWMian Wang
Mian Wang
PFPelagie Favi
Pelagie Favi
XCXiaoqian Cheng
Xiaoqian Cheng
NGNegar H. Golshan
Negar H. Golshan
KZKatherine S. Ziemer
Katherine S. Ziemer
TWThomas Webster
Thomas Webster

11 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MWMian Wang
Mian Wang
BHBenjamin Holmes
Benjamin Holmes
XCXiaoqian Cheng
Xiaoqian Cheng
WZWei Zhu
Wei Zhu
MKMichael Keidar
Michael Keidar
LZLijie Grace Zhang
Lijie Grace Zhang
Traditional breast cancer treatments such as surgery and radiotherapy contain many inherent limitations with regards to incomplete and nonselective tumor ablation. Cold atomospheric plasma (CAP) is an ionized gas where the ion temperature is close to room temperature. It contains electrons, charged particles, radicals, various excited molecules, UV photons and transient electric fields. These various compositional elements have the potential to either enhance and promote cellular activity, or disrupt and destroy them. In particular, based on this unique composition, CAP could offer a minimally-invasive surgical approach allowing for specific cancer cell or tumor tissue removal without influencing healthy cells. Thus, the objective of this research is to investigate a novel CAP-based therapy for selectively bone metastatic breast cancer treatment. For this purpose, human metastatic breast cancer (BrCa) cells and bone marrow derived human mesenchymal stem cells (MSCs) were separately treated with CAP, and behavioral changes were evaluated after 1, 3, and 5 days of culture. With different treatment times, different BrCa and MSC cell responses were observed. Our results showed that BrCa cells were more sensitive to these CAP treatments than MSCs under plasma dose conditions tested. It demonstrated that CAP can selectively ablate metastatic BrCa cells in vitro without damaging healthy MSCs at the metastatic bone site. In addition, our study showed that CAP treatment can significantly inhibit the migration and invasion of BrCa cells. The results suggest the great potential of CAP for breast cancer therapy.

1 December 2015 in Biointerphases
Verified
Journal Article
Closed access
PDF file
DYDayun Yan
Dayun Yan
ATAnnie Talbot
Annie Talbot
NNNiki Nourmohammadi
Niki Nourmohammadi
JSJonathan H. Sherman
Jonathan H. Sherman
XCXiaoqian Cheng
Xiaoqian Cheng
MKMichael Keidar
Michael Keidar
Selectively treating tumor cells is the ongoing challenge of modern cancer therapy. Recently, cold atmospheric plasma (CAP), a near room-temperature ionized gas, has been demonstrated to exhibit selective anticancer behavior. However, the mechanism governing such selectivity is still largely unknown. In this review, the authors first summarize the progress that has been made applying CAP as a selective tool for cancer treatment. Then, the key role of aquaporins in the H2O2 transmembrane diffusion is discussed. Finally, a novel model, based on the expression of aquaporins, is proposed to explain why cancer cells respond to CAP treatment with a greater rise in reactive oxygen species than homologous normal cells. Cancer cells tend to express more aquaporins on their cytoplasmic membranes, which may cause the H2O2 uptake speed in cancer cells to be faster than in normal cells. As a result, CAP treatment kills cancer cells more easily than normal cells. Our preliminary observations indicated that glioblastoma cells consumed H2O2 much faster than did astrocytes in either the CAP-treated or H2O2-rich media, which supported the selective model based on aquaporins.

30 September 2014 in Plasma Processes and Polymers
Verified
Journal Article
Closed access
PDF file
EREdward Ratovitski
Edward Ratovitski
XCXiaoqian Cheng
Xiaoqian Cheng
DYDayun Yan
Dayun Yan
JSJonathan H. Sherman
Jonathan H. Sherman
JCJerome Canady
Jerome Canady
MKMichael Keidar
Michael Keidar

30 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XCXiaoqian Cheng
Xiaoqian Cheng
JSJonathan Sherman
Jonathan Sherman
WMWilliam Murphy
William Murphy
EREdward Ratovitski
Edward Ratovitski
JCJerome Canady
Jerome Canady
Michael KeidarMichael Keidar
Michael Keidar
Previous research in cold atmospheric plasma (CAP) and cancer cell interaction has repeatedly proven that the cold plasma induced cell death. It is postulated that the reactive oxygen species (ROS) and reactive nitrogen species (RNS) play a major role in the CAP cancer therapy. In this paper, we seek to determine a mechanism of CAP therapy on glioblastoma cells (U87) through an understanding of the composition of the plasma, including treatment time, voltage, flow-rate and plasma-gas composition. In order to determine the threshold of plasma treatment on U87, normal human astrocytes (E6/E7) were used as the comparison cell line. Our data showed that the 30 sec plasma treatment caused 3-fold cell death in the U87 cells compared to the E6/E7 cells. All the other compositions of cold plasma were performed based on this result: plasma treatment time was maintained at 30 s per well while other plasma characteristics such as voltage, flow rate of source gas, and composition of source gas were changed one at a time to vary the intensity of the reactive species composition in the plasma jet, which may finally have various effect on cells reflected by cell viability. We defined a term “plasma dosage” to summarize the relationship of all the characteristics and cell viability.